Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Receivables - Other came in at -$706000.0 in Q4 2025, down 393.71% year-on-year from $240376.2 in Q4 2024, and down 197.11% on a QoQ basis from $727000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Receivables - Other (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Receivables - Other data on file, last reported at -$706000.0 in Q4 2025.
- On a quarterly basis, Receivables - Other fell 393.71% year-over-year to -$706000.0 in Q4 2025; TTM through Dec 2025 was -$1.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $177000.0, up 131.27% from the prior year.
- Receivables - Other for Q4 2025 stood at -$706000.0, down from $727000.0 in the prior quarter.
- Over the last five years, Receivables - Other for INBX reached as high as $952000.0 in Q2 2024 and fell as low as -$768000.0 in Q3 2024.
- Historically, Receivables - Other has averaged $251125.0 across 3 years, with a median of $608500.0 in 2023.
- On a YoY basis, Receivables - Other climbed as much as 194.66% in 2025 and fell as far as 393.71% in 2025.
- Year by year, Receivables - Other stood at $607000.0 in 2023, then slumped by 123.56% to -$143000.0 in 2024, then tumbled by 393.71% to -$706000.0 in 2025.
- Per Business Quant data, the three most recent Receivables - Other figures were -$706000.0 in Q4 2025, $727000.0 in Q3 2025, and $730000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -706,000.00 |
| Dec 31, 2025 | -706,000.00 |
| Sep 30, 2025 | 727,000.00 |
| Sep 30, 2025 | 727,000.00 |
| Jun 30, 2025 | 730,000.00 |
| Jun 30, 2025 | 730,000.00 |
| Dec 31, 2024 | -143,000.00 |
| Dec 31, 2024 | -143,000.00 |
| Sep 30, 2024 | -768,000.00 |
| Sep 30, 2024 | -768,000.00 |
| Jun 30, 2024 | 952,000.00 |
| Jun 30, 2024 | 952,000.00 |
| Mar 31, 2024 | 610,000.00 |
| Mar 31, 2024 | 610,000.00 |
| Dec 31, 2023 | 607,000.00 |
| Dec 31, 2023 | 607,000.00 |